; (ii) notifies the registrant if the order is an outlier and is potentially suspicious; (iii) is informed by all data available to the Administrator and uses pharmacy best practices; (iv) takes into consideration existing State and Federal law; and (v) establishes different parameters for different registrants using relevant information based on pharmacy type, location, and size. (B) Refinement The Administrator of the Drug Enforcement Administration (referred to in this section as the Administrator ) shall review, update, and revise the algorithm biannually based on feedback from industry and relevant stakeholders to ensure functionality. (3) Consultation The Administrator shall consult with the Director of the National Institute of Standards and Technology for technical assistance in establishing the clearinghouse. (c) Responsibilities of distributors and manufacturers regarding suspicious orders This section may not be construed as relieving any distributor or manufacturer from the requirements established in section 1301.74(b) of title 21, Code of Federal Regulations, or any successor regulation, with respect to suspicious orders. (d) Contractor regarding data analytics (1) In general The Administrator shall award a contract to a public or private entity enabling the Administrator to carry out the technological aspects of tracking, processing and evaluating orders under this section. (2) Eligible entities An entity is eligible for an award under paragraph (1) if the entity has significant experience in data analytics and in processing the volume of electronic data involved in reviewing orders under this section within the timeframe required in subsection (c). (3) Capabilities A contract awarded under paragraph (1) shall— (A) provide a data management and configurable visual analytics solution capable of ingesting and managing data entities, including manufacturers, and distributors, retail dispensers across relevant data maintained by the Administrator